1. Home
  2. ATNM vs LGCL Comparison

ATNM vs LGCL Comparison

Compare ATNM & LGCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • LGCL
  • Stock Information
  • Founded
  • ATNM 2000
  • LGCL 2009
  • Country
  • ATNM United States
  • LGCL China
  • Employees
  • ATNM N/A
  • LGCL N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • LGCL
  • Sector
  • ATNM Health Care
  • LGCL
  • Exchange
  • ATNM Nasdaq
  • LGCL NYSE
  • Market Cap
  • ATNM 56.5M
  • LGCL 48.3M
  • IPO Year
  • ATNM N/A
  • LGCL 2024
  • Fundamental
  • Price
  • ATNM $1.17
  • LGCL $0.52
  • Analyst Decision
  • ATNM Strong Buy
  • LGCL
  • Analyst Count
  • ATNM 4
  • LGCL 0
  • Target Price
  • ATNM $8.75
  • LGCL N/A
  • AVG Volume (30 Days)
  • ATNM 167.7K
  • LGCL 2.5M
  • Earning Date
  • ATNM 03-28-2025
  • LGCL 11-22-2024
  • Dividend Yield
  • ATNM N/A
  • LGCL N/A
  • EPS Growth
  • ATNM N/A
  • LGCL 11.49
  • EPS
  • ATNM N/A
  • LGCL 0.14
  • Revenue
  • ATNM $81,000.00
  • LGCL $173,306,912.00
  • Revenue This Year
  • ATNM $138.42
  • LGCL N/A
  • Revenue Next Year
  • ATNM $16,957.05
  • LGCL N/A
  • P/E Ratio
  • ATNM N/A
  • LGCL $3.76
  • Revenue Growth
  • ATNM N/A
  • LGCL N/A
  • 52 Week Low
  • ATNM $1.07
  • LGCL $0.47
  • 52 Week High
  • ATNM $10.24
  • LGCL $5.00
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 46.97
  • LGCL N/A
  • Support Level
  • ATNM $1.15
  • LGCL N/A
  • Resistance Level
  • ATNM $1.29
  • LGCL N/A
  • Average True Range (ATR)
  • ATNM 0.07
  • LGCL 0.00
  • MACD
  • ATNM 0.01
  • LGCL 0.00
  • Stochastic Oscillator
  • ATNM 46.51
  • LGCL 0.00

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.

Share on Social Networks: